Clinical characteristics of patients with IgM-MGUS according to the presence of the MYD88 (L265P) mutation
| Characteristic . | MYD88 (L265P) (n = 36) . | MYD88 wild-type (n = 41) . | P value . |
|---|---|---|---|
| Age (years), median (range) | 65 (36 to 83) | 62 (39 to 82) | .3 |
| Sex, number of patients (%) | |||
| Males | 23 (64%) | 19 (46%) | .17 |
| Females | 13 (36%) | 22 (54%) | .17 |
| Family history of lymphoid or myeloid disorders, number of patients (%) | 6/28 (21%) | 4/30 (13%) | .5 |
| Type of light chain, number of patients (%) | |||
| k | 26/36 (72%) | 25/40 (62%) | .12 |
| λ | 8/36 (22%) | 15/40 (38%) | .12 |
| K + λ | 2/36 (6%) | — | .12 |
| HCV infection, number of patients (%) | 4/31 (13%) | 4/37 (11%) | 1.0 |
| Hemoglobin (g/dL), median (range) | 13.4 (12 to 16.1) | 13.6 (8.3 to 16.6) | .63 |
| ESR (mm), median (range) | 25 (5 to 86) | 16 (1 to 102) | .05 |
| LDH (U/L), median (range) | 288 (174 to 459) | 308 (166 to 592) | .33 |
| β2 to microglobulin (mcg/L), median (range) | 1878 (1276 to 2850) | 1820 (1120 to 13600) | .92 |
| Serum albumin (g/dL), median (range) | 4.2 (3.1 to 4.9) | 4.2 (3.3 to 5.1) | .44 |
| IgG level (mg/dL), median (range) | 925 (82 to 3100) | 1070 (206 to 3487) | .04 |
| IgA level (mg/dL), median (range) | 141 (26 to 571) | 194 (34 to 2520) | .04 |
| IgM level (mg/dL), median (range) | 686 (243 to 4728) | 345 (116 to 1880) | Less than .0001 |
| Bence-Jones proteinuria, number of patients (%) | 14/34 (41%) | 3/37 (8%) | .002 |
| BM infiltration, number of patients (%) | |||
| By immunohistochemistry* | 9 (43%) | 12 (57%) | NS |
| By flow cytometry | 3 (4%) | 2 (3%) | NS |
| Characteristic . | MYD88 (L265P) (n = 36) . | MYD88 wild-type (n = 41) . | P value . |
|---|---|---|---|
| Age (years), median (range) | 65 (36 to 83) | 62 (39 to 82) | .3 |
| Sex, number of patients (%) | |||
| Males | 23 (64%) | 19 (46%) | .17 |
| Females | 13 (36%) | 22 (54%) | .17 |
| Family history of lymphoid or myeloid disorders, number of patients (%) | 6/28 (21%) | 4/30 (13%) | .5 |
| Type of light chain, number of patients (%) | |||
| k | 26/36 (72%) | 25/40 (62%) | .12 |
| λ | 8/36 (22%) | 15/40 (38%) | .12 |
| K + λ | 2/36 (6%) | — | .12 |
| HCV infection, number of patients (%) | 4/31 (13%) | 4/37 (11%) | 1.0 |
| Hemoglobin (g/dL), median (range) | 13.4 (12 to 16.1) | 13.6 (8.3 to 16.6) | .63 |
| ESR (mm), median (range) | 25 (5 to 86) | 16 (1 to 102) | .05 |
| LDH (U/L), median (range) | 288 (174 to 459) | 308 (166 to 592) | .33 |
| β2 to microglobulin (mcg/L), median (range) | 1878 (1276 to 2850) | 1820 (1120 to 13600) | .92 |
| Serum albumin (g/dL), median (range) | 4.2 (3.1 to 4.9) | 4.2 (3.3 to 5.1) | .44 |
| IgG level (mg/dL), median (range) | 925 (82 to 3100) | 1070 (206 to 3487) | .04 |
| IgA level (mg/dL), median (range) | 141 (26 to 571) | 194 (34 to 2520) | .04 |
| IgM level (mg/dL), median (range) | 686 (243 to 4728) | 345 (116 to 1880) | Less than .0001 |
| Bence-Jones proteinuria, number of patients (%) | 14/34 (41%) | 3/37 (8%) | .002 |
| BM infiltration, number of patients (%) | |||
| By immunohistochemistry* | 9 (43%) | 12 (57%) | NS |
| By flow cytometry | 3 (4%) | 2 (3%) | NS |
ESR, erythrocyte sedimentation rate; HCV, hepatitis C virus; LDH, lactate dehydrogenase; NS, not significant.
Median BM infiltration by immunohistochemistry 5% (range 1 to 10).